Mazzariello Gina sold $539K of AMLX
Mazzariello Gina (Chief Legal Officer) sold 30,000 shares of Amylyx Pharmaceuticals, Inc. (AMLX) at an average of $17.96 ($17.61–$18.32, $0.54M total) across 2 trades over 2026-07-09 to 2026-07-10 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a concrete datapoint on insider selling activity, but it does not introduce new company fundamentals or catalysts.
Market read
For AMLX, this is a routine insider sale update with limited expected impact absent other news.
What to watch
Traders may over-weight insider sales; without accompanying buy transactions, guidance changes, or material events, the signal is usually weak.
Background
The article is an SEC Form 4 insider transaction by Amylyx Pharmaceuticals’ Chief Legal Officer, reported as open-market sales under a 10b5-1 plan.
Ticker impact
Amylyx Pharmaceuticals CFO Gina Mazzariello sold 30,000 shares in open-market trades under a pre-arranged 10b5-1 plan, totaling about $538,867.
Likely minimal, with any impact more sentiment-driven than fundamental.
The filing is a routine Form 4 open-market sale by an officer under a pre-arranged 10b5-1 plan; no new operational, clinical, or financial guidance is disclosed.
Market effects
No direct sector read-through; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.
Key entities
- issuerAmylyx Pharmaceuticals, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderGina Mazzariello
Chief Legal Officer who sold shares under a 10b5-1 plan.
